The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
PreviousPrevious
Volume 349:629-630 August 14, 2003 Number 7
NextNext

Trial Design and Patient Safety — The Debate Continues
Robert Steinbrook, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
On July 3, 2003, nearly a year after it first became involved, the Office for Human Research Protections (OHRP) of the Department of Health and Human Services released its decision about two disputed multicenter clinical trials of treatment for the acute respiratory distress syndrome (ARDS).1,2 In a 15-page letter, the office seems to substantiate the ethical appropriateness and research design of both trials and to refute concern that participants were subjected to unnecessary risks. The OHRP does this by referring to the opinions of outside consultants whom it retained, without taking a position on the controversy itself. However, the OHRP, . . . [Full Text of this Article]


Related Letters:

The Office for Human Research Protections and the NIH
Beck R. W.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:2076-2077, Nov 20, 2003. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.